Not surprisingly, genome-wide DNA sequencing showed that the sensitivity of HNSCC patients to cetuximab is not only dependent on EGFR mutation status, but generally fluctuates with mutations in these additional EGFR pathway genes. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.